(NRXP) is highlighted for its role in transitioning the ketamine market from off-label use to standardized care.
Coverage has been initiated with a Buy rating and $49 price target, reflecting strong expectations for the company’s clinical and commercialization strategy.
READ HERE
https://bit.ly/NRXpressrelease
Learn more at https://bit.ly/NRXPharmaceuticals
Watch the
@NewToTheStreet
interview here
https://bit.ly/NTTS-NRXPharmaAdvancesKetamineTherapy
#NRX #pharma #healthcare #biotechnews #innovation #businessupdate #businessnews #business #news #newtothestreet